Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma

Carfilzomib (Kyprolis®), a second generation proteasome inhibitor, is FDA approved for single-agent use among relapsed/refractory multiple myeloma (MM). To enhance the therapeutic efficacy of carfilzomib, we sought to combine carfilzomib with other novel agents. TG02, a multi-kinase inhibitor, targe...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Biol Ther
Autors principals: Ponder, Katelyn G., Matulis, Shannon M., Hitosugi, Sadae, Gupta, Vikas A., Sharp, Cathy, Burrows, Francis, Nooka, Ajay K., Kaufman, Jonathan L., Lonial, Sagar, Boise, Lawrence H.
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2016
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4970534/
https://ncbi.nlm.nih.gov/pubmed/27246906
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2016.1192086
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars